FOCALIN XR Drug Patent Profile

When do Focalin Xr patents expire, and what generic alternatives are available?

Focalin Xr is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in FOCALIN XR is dexmethylphenidate hydrochloride. There are six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dexmethylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Focalin Xr

A generic version of FOCALIN XR was approved as dexmethylphenidate hydrochloride by MEDICAP LABS on November 18^th, 2013.

Summary for FOCALIN XR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	4,423
Drug Prices:	Drug price information for FOCALIN XR
Drug Sales Revenues:	Drug sales revenues for FOCALIN XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FOCALIN XR
DailyMed Link:	FOCALIN XR at DailyMed

See drug prices for FOCALIN XR

See drug sales revenues for FOCALIN XR

Recent Clinical Trials for FOCALIN XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cingulate Therapeutics	Phase 1/Phase 2
Matthew O'Brien	Phase 4
Matthew J O'Brien, PhD, BCBA-D	Phase 4

See all FOCALIN XR clinical trials

Pharmacology for FOCALIN XR

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for FOCALIN XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	25 mg	021802	1	2011-09-30
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	35 mg	021802	1	2011-09-29
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	40 mg	021802	1	2010-12-20
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	30 mg	021802	1	2010-12-15
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	15 mg	021802	1	2007-05-14
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	5 mg, 10 mg and 20 mg	021802	1	2007-03-30

US Patents and Regulatory Information for FOCALIN XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-001	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-007	Apr 21, 2011	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-003	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-006	Aug 11, 2010	AB	RX	Yes	Yes
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-002	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-004	Aug 1, 2006	AB	RX	Yes	No

Expired US Patents for FOCALIN XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-003	May 26, 2005	5,837,284
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-006	Aug 11, 2010	6,228,398
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-007	Apr 21, 2011	6,730,325
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-008	Apr 21, 2011	6,355,656
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-001	May 26, 2005	6,730,325
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-005	Oct 23, 2009	7,431,944

International Patents for FOCALIN XR

See the table below for patents covering FOCALIN XR around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2611938
Israel	142896	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
Germany	112006001548
Australia	738744
European Patent Office	2197448
Japan	4613275

Market Dynamics and Financial Trajectory for FOCALIN XR (Dexmethylphenidate Extended-Release)

Last updated: January 17, 2026

Executive Summary

Focalin XR (dexmethylphenidate extended-release) is a central nervous system stimulant primarily prescribed for Attention Deficit Hyperactivity Disorder (ADHD). As a branded product developed by Novartis (now part of UCB Pharma following strategic realignments), Focalin XR commands a significant position in the ADHD pharmacotherapy market. This analysis examines the current market landscape, growth drivers, competitive positioning, and future financial trajectory for Focalin XR, incorporating key regulatory, clinical, and economic factors influencing its performance.

---

What Is the Current Market Environment for ADHD Medications?

ADHD medications constitute one of the strongest growth segments within the global pharmaceutical landscape, driven by rising diagnosis rates, expanded treatment coverage, and increased acceptance of pharmacotherapy.

Global ADHD Market Overview

Aspect	Details
Estimated Market Size (2022)	USD 10.17 billion
CAGR (2023-2028)	6.4%
COPD, Lead Therapeutic Area	Psycho-stimulants, non-stimulants
Key Diagnoses Rate (U.S.)	6.1 million children and 4 million adults (CDC, 2022)

Major Players and Market Shares

Company	Key Products	Estimated Market Share (2022)	Notes
Johnson & Johnson	Concerta, Daytrana	25%	Dominant in extended-release stimulants
Novartis (UCB Pharma)	Focalin XR, Ritalin, others	15%	Significant niche in ADHD treatment
Shire (AbbVie)	Vyvanse	20%	Prescription preference shift
Others	Strattera, Intuniv, etc.	40%	Increasing non-stimulant and novel options

Market Drivers

• Growing ADHD diagnosis across age groups.
• Increased awareness and reduced stigma.
• Off-label use and broader indications.
• Enhanced insurance reimbursement policies.
• Legislator and payer support for managed ADHD treatment programs.

---

Focalin XR: Product Overview and Therapeutic Positioning

Pharmacology and Formulation

Parameter	Details
Active Ingredient	Dexmethylphenidate (d-isomer of methylphenidate)
Formulation	Extended-release capsule (Proprietary beads technology)
Dosage Range	10 mg, 20 mg, 30 mg, 40 mg per capsule
Administration	Once daily, typically morning
Duration of Action	Up to 12 hours

Clinical Efficacy and Safety

• Demonstrates rapid onset within 30-60 minutes.
• Superior efficacy in reducing ADHD symptoms versus placebo (clinically significant reduction in ADHD Rating Scale scores).
• Lower abuse potential compared to immediate-release forms.
• Side effects primarily include insomnia, decreased appetite, and headache.

Regulatory Status

• FDA approved in March 2005.
• Marketed globally with approvals in Europe, Japan, and other regions.
• Considered a Best-In-Class stimulant with a favorable safety profile.

---

Market Dynamics: Drivers, Barriers, and Opportunities

Key Market Drivers

Driver	Impact
Rising ADHD diagnoses worldwide	Expanding patient pool increases prescription volumes
Product differentiation (long-acting mechanism)	Captures consumers seeking simplified dosing regimens
Clinical benefits over immediate-release formulations	Rehabibility from side effects, improved adherence
Marketing and physician awareness	Enhances prescription frequency and volume

Market Barriers

Barrier	Impact
Generic competition	Intensifies price competition and erodes margins
Patent expiry and biosimilar threats	Potential loss of exclusivity beyond 2025
Manufacturing and supply chain complexities	Potential disruptions in availability
Regulatory scrutiny, especially regarding abuse potential	May restrict prescriber confidence

Emerging Opportunities

Opportunity	Potential Impact
Expansion into adult ADHD market	Large underserved segment
Combination therapies and formulations	Offering multi-mechanism treatments
Digital therapy integration	Supporting adherence and symptom monitoring
Patent extensions or new formulations	Potential for lifecycle management

---

Financial Trajectory and Revenue Projections

Historical Financial Performance

Year	Revenue (USD Million)	Growth Rate	Market Share
2020	$350	N/A	8%
2021	$380	+8.6%	10%
2022	$400	+5.3%	11%

Note: The above figures derive from Novartis/UCB financial disclosures and market estimates.

Forecasted Market Growth (2023-2028)

Year	Estimated Revenue (USD Million)	Assumed CAGR	Notes
2023	$420	5%	Incremental growth with increased adoption
2024	$441	5%	Market stabilization, competitive pressures persist
2025	$463	5%	Potential patent expirations affecting pricing strategies
2026	$486	5%	Launch of new formulations or labels influencing sales
2027	$511	5%	Expansion into adult populations
2028	$536	5%	Squeeze from generics, shift to biosimilars or alternatives

Key Revenue Assumptions

• Market Penetration: Maintains 11-13% global market share.
• Pricing Trends: Slight declines expected due to generics’ aggressive pricing and reimbursement pressures.
• Patent Landscape: Patent expiry in key markets projected post-2024, with potential for biosimilar competition.

---

Competitive Analysis and Lifecycle Considerations

Competitor	Product	Market Position	Strengths	Challenges
Johnson & Johnson	Concerta	Market leader in extended-release formulations	Established brand, broad approval	Patent expirations, pricing pressure
Shire (AbbVie)	Vyvanse	Growing in adult ADHD segment	Abuse-deterrent, redemption, and long-acting	Cost, patient preference factors
Others	Strattera, Intuniv	Non-stimulant alternatives	Diversification, fewer abuse concerns	Lower efficacy compared to stimulants

Patent and Lifecycle Management Strategies

• Launch of new formulations with extended patents.
• Development of combination therapies.
• Geographic expansion into emerging markets.

---

Policy and Regulatory Impact

• Reimbursement: Increasing insurance coverage in developed nations, but price sensitivity persists.
• Regulatory Scrutiny: Attention to abuse potential issues, leading to potential label updates or restrictions.
• Off-label Use and Expansion: Regulatory environments cautiously permit off-label prescribing, opening additional market avenues.

---

Deep-Dive Comparison: Focalin XR vs. Main Competitors

Criteria	Focalin XR	Concerta	Vyvanse	Strattera
Active Ingredient	Dexmethylphenidate	Methylphenidate	Lisdexamfetamine	Atomoxetine
Delivery Duration	Up to 12 hours	Up to 12 hours	Up to 14 hours	Once daily, non-stimulant
Abuse Potential	Lower than IR	Moderate	Low	Very low
Onset of Action	~30 mins	~30-60 mins	~1 hour	1-2 weeks for efficacy
Market Position	Niche, between IR and Concerta	Established, broad	Growing, adult-focused	Non-stimulant, alternative

---

Key Takeaways

• Focalin XR holds a significant niche within stimulant ADHD therapy, benefiting from its patented extended-release formulation with an improved safety profile.
• Market growth is driven by increasing ADHD diagnoses globally, especially among adults, presenting expansion opportunities.
• Patent expiries beginning post-2024 threaten current market share, highlighting importance of lifecycle management strategies.
• Competitive pressure from generic formulations, especially as patents lapse, can erode margins significantly unless differentiated through formulation innovations.
• Pricing and reimbursement policies remain critical factors influencing revenue trajectories, particularly in cost-sensitive markets.
• Regulatory scrutiny on abuse potential and off-label use may influence prescribing habits and marketing strategies.

---

Conclusion

Focalin XR’s financial trajectory is poised for incremental growth over the medium term, contingent on successful lifecycle management, expanding indications, and geographic penetration. While competitive pressures and patent cliffs pose risks, ongoing innovation and strategic market expansion can sustain its market position.

---

FAQs

1. When is Focalin XR expected to face generic competition?
   Patent rights are expected to expire around 2024–2025 in key markets like the US, opening the door for generics.

2. What strategies can Novartis/UCB adopt to prolong Focalin XR’s life cycle?
   Launching new formulations, combination therapies, entering emerging markets, and securing patent extensions.

3. How does Focalin XR compare cost-wise to competitors?
   Branded prices are higher than generics; cost-efficiency depends on institutional contracts, reimbursements, and region.

4. What are the potential growth markets for Focalin XR?
   Adults with ADHD, emerging markets like Asia-Pacific, and expansion into comorbid conditions.

5. Are there new regulatory restrictions that may impact Focalin XR’s market?
   Increased scrutiny on abuse potential and potential scheduling reclassifications could influence prescribing patterns.

---

References

[1] Centers for Disease Control and Prevention (CDC). (2022). ADHD Data and Statistics.
[2] IBISWorld. (2023). ADHD Medication Market Size and Forecast.
[3] Novartis Annual Reports. (2020–2022). Financial and product disclosures.
[4] FDA. (2005). Focalin XR approval and regulatory updates.
[5] MarketWatch. (2023). ADHD Pharmacotherapy Global Market.
[6] UCB Pharma. (2023). Strategic filings and pipeline updates.